Bora Pharma Completes Acquisition of MacroGenics CDMO Business, Aims for US Contract Manufacturing

(CNA) - Bora Pharma's board of directors approved in May the acquisition of the CDMO (Contract Development and Manufacturing Organization) business spun off from US biopharmaceutical company MacroGenics for a total transaction amount of US$122.5 million (approximately NT$3.9 billion). Bora announced today that the acquisition has been completed, and it will fully target the lucrative US pharmaceutical contract manufacturing market.

Bora stated that the acquisition includes the large-molecule manufacturing facility in Rockville, Maryland (hereinafter referred to as the Rockville plant) and a warehousing center in Frederick. The transaction has been officially completed as of today by Bora Biologics USA, a wholly-owned subsidiary. Concurrently, Bora has signed a CDMO service agreement with MacroGenics, continuing to provide contract manufacturing services for them.

Bora emphasized that with the completion of this transaction, the Rockville plant in Maryland, the San Diego plant in California belonging to Tai-Foong Biotech, and an early-stage development site in Zhubei, Taiwan, all operate under Bora Pharma's biologics CDMO brand, Bora Biologics. In total, Bora Biologics possesses a raw material drug manufacturing capacity of 20,000 liters using single-use bioreactors (SUB).

Bora will entrust Tai-Foong Biotech as the sole business development team for the Bora Biologics brand. The group will coordinate resources and focus on business development and commercial execution. With a larger production scale, more comprehensive commercial manufacturing experience, and a richer track record of regulatory inspections, Bora will accelerate the expansion of late-stage clinical and commercial projects, enhancing its international visibility.

Bora Pharma Chairman and CEO, Dr. Pei-Hsiu Sheng, stated that with the expansion of Bora Biologics, Bora looks forward to establishing a reliable US-based biologics manufacturing platform for its pharmaceutical clients, covering everything from development to stable post-approval commercial supply.

Dr. Sheng pointed out that Bora has observed continuous changes in regulatory and supply chain landscapes in recent years. He anticipates that these developments will drive biopharmaceutical companies to increasingly seek manufacturing partners with infrastructure that has been inspected and validated by US regulatory authorities and the market. To meet this demand, Bora has deployed group resources to build a fully integrated, end-to-end biologics contract manufacturing platform with capabilities spanning both raw materials and finished drug products. This plan officially commences with the handover of the Rockville plant.

Bora stated that with the addition of the Rockville plant, Bora Biologics now supports over 4 commercial production projects, has completed over 120 GMP batches, and supplies multiple major global markets including the United States, European Union, Japan, Canada, and the United Kingdom, possessing integrated quality control and analytical capabilities.

Bora Pharma plans to integrate its US raw material drug (DS) capabilities with its existing sterile drug product (DP) capabilities within the next 12 to 18 months, offering global clients a seamless, single-team biological drug solution for the US market, from development to commercialization. (Editor: Yang Lan-hsuan) 1150703

Stand with facts, your every contribution is a force to protect the freedom of the press.

Download the CNA "One News" APP to grasp the latest news in real-time.

Text, images, and videos on this website may not be reproduced, publicly broadcast, publicly transmitted, or used without authorization.